"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
| Descriptor ID |
D017024
|
| MeSH Number(s) |
E02.186.170 E02.319.170
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".
This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 5 | 6 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 3 | 3 |
| 2016 | 2 | 4 | 6 |
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
| 2025 | 0 | 5 | 5 |
| 2026 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.
-
Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer. JNCI Cancer Spectr. 2026 Nov 02; 10(6).
-
Self-reported racial and ethnic discrimination in patient-provider interactions and the initiation of adjuvant therapies for breast cancer in the pathways study. Breast Cancer Res Treat. 2026 Aug 10; 218(3).
-
Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast?cancer. J Natl Cancer Inst. 2026 Jul 01; 118(7):1278-1289.
-
The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancer. Cancer. 2026 Mar 15; 132(6):e70318.
-
Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancer. Cancer. 2026 Mar 01; 132(5):e70294.
-
Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer. J Natl Cancer Inst. 2026 Feb 01; 118(2):307-315.
-
Is age just a number? Oncotype DX testing and chemotherapy use in the post-TAILORx era. Cancer. 2025 Dec 15; 131(24):e70218.
-
Evaluation of methods to identify chemotherapy-related hematologic toxicities in real-world settings. Int J Cancer. 2026 Mar 15; 158(6):1481-1488.
-
Evaluating Long-Term Health Disparity Impacts of Clinical Algorithms Using a Patient-Level Simulation Framework. Value Health. 2026 03; 29(3):357-365.
-
Beyond the 5-year mark: adherence to and continuation of extended adjuvant endocrine therapy in non-metastatic breast cancer patients. Breast Cancer Res Treat. 2025 Nov; 214(2):239-246.